| dc.contributor.author | Sharp, A | |
| dc.contributor.author | Welti, J | |
| dc.contributor.author | Blagg, J | |
| dc.contributor.author | de Bono, JS | |
| dc.date.accessioned | 2017-03-02T11:34:41Z | |
| dc.date.issued | 2016-09-01 | |
| dc.identifier.citation | Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 22 (17), pp. 4280 - 4282 | |
| dc.identifier.issn | 1078-0432 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/464 | |
| dc.identifier.eissn | 1557-3265 | |
| dc.identifier.doi | 10.1158/1078-0432.ccr-16-1137 | |
| dc.description.abstract | Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ©2016 AACRSee related article by Yang et al., p. 4466. | |
| dc.format | Print-Electronic | |
| dc.format.extent | 4280 - 4282 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.publisher | AMER ASSOC CANCER RESEARCH | |
| dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
| dc.subject | Animals | |
| dc.subject | Humans | |
| dc.subject | Mice | |
| dc.subject | Receptors, Androgen | |
| dc.subject | Antineoplastic Agents | |
| dc.subject | Alternative Splicing | |
| dc.subject | Male | |
| dc.subject | Protein Interaction Domains and Motifs | |
| dc.subject | Molecular Targeted Therapy | |
| dc.subject | Androgen Receptor Antagonists | |
| dc.subject | Prostatic Neoplasms, Castration-Resistant | |
| dc.title | Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer. | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2016-05-26 | |
| rioxxterms.versionofrecord | 10.1158/1078-0432.ccr-16-1137 | |
| rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
| rioxxterms.licenseref.startdate | 2016-09 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | Clinical cancer research : an official journal of the American Association for Cancer Research | |
| pubs.issue | 17 | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1 | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1 | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics | |
| pubs.publication-status | Published | |
| pubs.volume | 22 | |
| pubs.embargo.terms | Not known | |
| icr.researchteam | Medicinal Chemistry 1 | |
| icr.researchteam | Prostate Cancer Targeted Therapy Group | |
| icr.researchteam | Translational Therapeutics | |
| dc.contributor.icrauthor | Sharp, Adam | |
| dc.contributor.icrauthor | De Bono, Johann | |
